U.S. FDA approves TG Therapeutics' multiple sclerosis drug; shares surge
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Cantor Fitzgerald Explains Drivers of TG Therapeutics (TGTX) Performance Today
December 29, 2022 11:06 AM ESTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and $40.00 price target on TG Therapeutics (NASDAQ: TGTX).
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some... More
Cantor Fitzgerald Keeps $40 PT on TG Therapeutics (TGTX), 'Label Looks Clean & Slightly Better Than Expectations'
December 28, 2022 2:18 PM ESTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and $40.00 price target on TG Therapeutics (NASDAQ: TGTX)
The analyst comments "Ublituximab (brand name: Briumvi) was just (PDUFA: 12/28) approved by the FDA for the treatment of relapsing forms of Multiple Sclerosis (MS) label... More
TG Therapeutics (TGTX) to Resume Trading at 2:20 p.m.
December 28, 2022 1:55 PM ESTTG Therapeutics (NASDAQ: TGTX) to Resume Trading at 2:20 p.m.
... MoreTG Therapeutics (TGTX) Confirms FDA Approval of BRIUMVI (ublituximab-xiiy)
December 28, 2022 1:49 PM ESTTG Therapeutics, Inc. (NASDAQ: TGTX) today announced the U.S. Food and Drug Administration (FDA) has approved BRIUMVI (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Approval was granted for this indication based on data from the ULTIMATE I & II Phase 3 trials, which demonstrated superiority over teriflunomide in significantly reducing the annualized relapse rate (ARR, the primary endpoint), the number of T1 Gd-enhancing lesions and the number of new or enlarging T2 lesions. Results... More
